Department of Internal Medicine, University of Toledo, Toledo, Ohio.
Penn State Heart and Vascular Institute, Penn State University, Hershey Pennsylvania.
Am J Med Sci. 2019 Jan;357(1):67-74. doi: 10.1016/j.amjms.2018.07.004. Epub 2018 Jul 17.
Hemophagocytic lymphohistiocytosis (HLH) is a rare disease of massive, dysregulated cytokine release and secondary multiorgan failure and is associated with high mortality. Primary HLH occurs predominately in infants and young children with a genetic predisposition. Acquired HLH is less well characterized and usually occurs in younger adults in the setting of severe inflammation triggered by infection or malignancy. Little is known about the disease in elderly. We report 3 patients >50 years old who presented with multiorgan failure and shock without an identifiable source and were ultimately diagnosed with acquired HLH. We performed a literature review of HLH in adults >50 years of age and identified an additional 68 cases. Mean age was 62 years, with male predominance. Most cases were triggered by infection (49%) followed by malignancy (27%). Nineteen patients were treated with the HLH-94 protocol, 11 received corticosteroids and the remainder received non-HLH specific interventions. Overall mortality was 62%.
噬血细胞性淋巴组织细胞增生症(HLH)是一种罕见的疾病,其特征为大量细胞因子失调释放和继发性多器官衰竭,并伴有高死亡率。原发性 HLH 主要发生在有遗传易感性的婴儿和幼儿中。获得性 HLH 的特征不太明确,通常发生在年轻成年人中,由感染或恶性肿瘤引发的严重炎症触发。关于老年人的这种疾病知之甚少。我们报告了 3 名年龄 >50 岁的患者,他们表现为多器官衰竭和休克,没有明确的病因,并最终被诊断为获得性 HLH。我们对年龄 >50 岁的成人 HLH 进行了文献回顾,共确定了另外 68 例。平均年龄为 62 岁,男性居多。大多数病例是由感染(49%)引起的,其次是恶性肿瘤(27%)。19 例患者接受了 HLH-94 方案治疗,11 例患者接受了皮质类固醇治疗,其余患者接受了非 HLH 特异性干预。总体死亡率为 62%。